Straits Times Index
3,314.14 +8.12 (+0.25%) S&P 500
5,464.62 -8.55 (-0.16%) Dow
39,150.33 +15.53 (+0.04%) Nasdaq
17,689.36 -32.24 (-0.18%) Bitcoin USD
61,163.46 -3,160.17 (-4.91%) CMC Crypto 200
1,267.12 -42.60 (-3.25%)
PURE Bioscience, Inc. (PURE)
| Previous close | 0.0750 |
| Open | 0.0710 |
| Bid | 0.0621 x 0 |
| Ask | 0.1150 x 0 |
| Day's range | 0.0710 - 0.0750 |
| 52-week range | 0.0600 - 0.1700 |
| Volume | |
| Avg. volume | 25,461 |
| Market cap | 8.389M |
| Beta (5Y monthly) | 0.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | 14 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WirePURE Bioscience Announces an International Supply and License Agreement with AgroVet Alliance
EL CAJON, Calif., June 18, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and AgroVet Alliance, FZE ("AVA"), have entered into a multi-year international supply and license agreement for the purchase and selling of SDC products under special terms and conditions.
Business WirePURE Bioscience Reports Fiscal Third Quarter 2024 Financial Results
EL CAJON, Calif., June 14, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024.
Business WirePURE Bioscience Appoints Darin Zehr to Board of Directors
EL CAJON, Calif., May 06, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported the appointment of Darin Zehr to its Board of Directors, effective as of May 1, 2024.
